Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited Janssen, the company manufacturing abiraterone acetate (AA; tradename Zytiga(®)), to submit evidence for the clinical and cost effectiveness of AA in combination with prednisone/prednisolone (AAP) compared with watchful waiting (i....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Pharmacoeconomics
Autori principali: Ramaekers, Bram L. T., Riemsma, Rob, Tomini, Florian, van Asselt, Thea, Deshpande, Sohan, Duffy, Steven, Armstrong, Nigel, Severens, Johan L., Kleijnen, Jos, Joore, Manuela A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2016
Soggetti:
Review Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5253156/
https://ncbi.nlm.nih.gov/pubmed/27566699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-016-0445-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi